Recce Limited
Recce Pharmaceuticals Ltd (ASX: RCE, FSE:R9Q) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs.
Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.
Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results to date. Recce Pharmaceuticals has manufacturing facilities in Australia and clinical research partners in the USA.
Recce Pharmaceuticals has validated an automated process to manufacture its lead compound ahead of first-in-human clinical trials.
Product : Pharmaceuticals, sepsis, virus, polymers, biotechnology, synthetic polymers, antibiotics, global health, antibiotic resistance, clinical trials, sepsis, infectious disease , FDA and ASX.
Contact Info:
Address: L36, 1 Macquarie Place, Gateway Tower, Sydney, NSW 2000, AU
Website: www.recce.com.au
Phone: 61(2) 9256 2571
